Acinetobacter baumannii Complex Infections: New Treatment Options in the Antibiotic Pipeline
Microorganisms · 07.02.2025 · 13 (2) · 356
DOI: 10.3390/microorganisms13020356 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Microorganisms, online erschienen am 07.02.2025. Verfasst von Noayna Arshad und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Medstar Washington Hospital Center, Washington, DC 20010, USA. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Acinetobacter baumannii complex (ABC) can result in a panoply of severe syndromes, including pneumonia and septic shock. Options available for treating infections caused by ABC and, more importantly, by carbapenem-resistant ABC (CRAB) are limited because of the increasing prevalence of antimicrobial resistance. Furthermore, many older agents, such as polymyxin and colistin, have limited lung penetration and are associated with significant toxicities. These factors underscore the urgent need for new paradigms to address ABC and CRAB. Two agents, cefiderocol and sulbactam-durlobactam, are now available to treat CRAB infections. In addition, several anti-infectives that target CRAB are in later-stage clinical trials. In order to place these newer molecules in context and to help clinicians appreciate the emerging potential drug development pipeline, we describe the in vitro activity, mechanisms of action, and clinical trial data not only for the commercially now available alternatives, such as cefiderocol and sulbactam-durlobactam, but also review these topics for molecules undergoing phase II and III clinical trials. Specifically, we discuss and analyze data related to four novel drugs from ABC: BV-100, cefepime-zidebactam, zosurabalpin, and OMN6.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Medstar Washington Hospital Center, Washington, DC 20010, USA.
- EviMed Research Group, LLC, Goshen, MA 01032, USA.
- Pulmonary and Critical Care Medicine, Medstar Washington Hospital Center, Washington, DC 20010, USA.
ORCID-Profile: Andrew F Shorr
Zitieren
APA
Arshad, N., Azzam, W., Zilberberg, M. D., & Shorr, A. F. (2025). Acinetobacter baumannii Complex Infections: New Treatment Options in the Antibiotic Pipeline. Microorganisms, 13(2), 356. https://doi.org/10.3390/microorganisms13020356
Vancouver
Arshad N, Azzam W, Zilberberg MD, Shorr AF. Acinetobacter baumannii Complex Infections: New Treatment Options in the Antibiotic Pipeline. Microorganisms. 2025;13(2):356. doi:10.3390/microorganisms13020356
BibTeX
@article{Arshad2025,
author = {Arshad, Noayna and Azzam, Wael and Zilberberg, Marya D and Shorr, Andrew F},
title = {Acinetobacter baumannii Complex Infections: New Treatment Options in the Antibiotic Pipeline},
journal = {Microorganisms},
year = {2025},
volume = {13},
number = {2},
pages = {356},
doi = {10.3390/microorganisms13020356}
}
EUVIMED